A pharmaceutical composition for increasing melanin synthesis in hair follicles
Patent Information
- Application Number
- PCT/TR2024/050443
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-14
Smart Images

Figure IMGF000008_0001 
Figure 00000011_0000
Abstract
Description
[0001] DESCRIPTION
[0002] A PHARMACEUTICAL COMPOSITION FOR INCREASING MELANIN SYNTHESIS IN HAIR FOLLICLES
[0003] Technical Field
[0004] The invention relates to a pharmaceutical composition developed to convert white body hair, particularly hair, back to its original color. The invention is particularly related to a composition that works based on increasing melanin synthesis by regulating melanocyte cells. The pharmaceutical composition of the present invention is applied to the scalp by intradermal method.
[0005] Prior Art
[0006] Aging is a physiological process that humans cannot prevent, and during this process, whitening or shedding of hair is often observed, especially after the age of fifty. Although the exact cause of whitening or shedding of hair is not fully understood, it is one of the most important signs of biological aging in humans. Various stem cells are involved in the regeneration of hair follicles, and these stem cells produce melanocytes, which give color to the hair. Whitening of the hair begins when there is a dysfunction or death of melanocytes. Various methods are resorted to in the prior art for coloring whitened hair and body hair. These can generally be listed as follows:
[0007] Hair dyes
[0008] Hair lotions
[0009] Use of certain vitamins and minerals (Biotin, Calcium pantothenate, Zinc, Copper, Selenium, etc.)
[0010] Systemic use of P-aminobenzoic acid (PABA) (However, the use of PABA on hair is highly controversial due to its side effects and its duration of action is very short.) Systemic or topical psoralen and UVA phototherapy (PUVA)
[0011] Topical prostaglandins (latanoprost etc.)
[0012] Herbal approaches applied to the scalp, such as hair oils; coconut, olive and almond oils, mineral oils, etc.
[0013] Systemic antioxidants (such as SkQs)
[0014] Patent studies have also been conducted on this subject in the prior art. Japanese Patent No: JP2001288098A discloses a melanin production enhancer containing plant extracts such as ginseng, yucca, and new world (name of a fruit). Japanese Patent No: JP2001048754A discloses a composition containing a melanocyte growth factor that supports the growth of melanocytes. Japanese Patent No: JP2002047130A relates to a melanin production enhancer containing fig, mulberry, or their extract. International Patent No: W02012091730A2 discloses a method of applying an indole alkaloid compound to increase melanin content.
[0015] In the methods and studies mentioned above, the state of art is revealed. Essentially, through these methods except for hair dyes and hair lotions, it is either impossible to achieve a noticeable effect or the effect is very short-lived. Furthermore, it is necessary not to overlook the significant side effects of the applied methods. Finally, hair dyes and hair coloring lotions cannot restore the original color of the hair. However, they work by dyeing the hair shaft based on the coloring agents in their content.
[0016] Variation in human hair color results from the fact that different types of melanins, called eumelanin (brown-black color) and pheomelanin (yellow-red color) in the hair cortex, are produced in varying proportions by the body.
[0017] Melanocytes are cells that produce pigment. The melanin synthesis and distribution processes that occur in melanocytes among the basal cells of the epidermis is called melanogenesis. Melanocytes are responsible for synthesizing melanin in special organelles called melanosomes included within their structures and for transferring melanosomes to neighboring keratinocytes to protect them from UV radiation.
[0018] Melanin is a pigment found in mammalian cells responsible for coloration. It is included in the skin, hair, ciliary body (corpus ciliar) in the eye, and leptomeninges and substantia nigra in the brain and iris. Melanin is synthesized from cells called melanocytes. Melanocytes, which are the branching and long elongated cells, originate from the neural crest in the embryo and migrate to the skin and other body parts. Melanocytes are cells with tyrosinase activity. With the help of this enzyme, tyrosine, which reaches to the melanocyte cytoplasm through blood flow, is converted into melanin, and this product is stored in granules surrounded by a membrane derived from the Golgi corpuscle, called melanosomes. Mature melanosomes progress towards the cytoplasmic extensions of melanocytes in the skin and then pass to keratinocytes from there. This transition occurs when keratinocytes phagocytose the granules. The melanin granules that pass to keratinocytes gather on the nuclei of these cells and thus protect them from the harmful effects of ultraviolet rays. The process of melanin synthesis and distribution that occurs within melanocytes included among the basal cells of the epidermis is called melanogenesis. Melanogenesis process is mostly defined by two different pathways: (i) melanosome biogenesis and (ii) the biochemical pathway where phenylalanine / L-tyrosine is converted to melanin. Intermediate metabolites and reactions in melanin synthesis are shown in Figure-1.
[0019] The biochemical pathway is in a way such that melanogenesis is induced through activation of intracellular signaling pathways such as protein kinase C (PKC), nitric oxide (NO), and cyclic AMP (cAMP) via melanogenic factors which is synthesized from mast cells, melanocytestimulating hormone (MSH), UV rays of which are released from keratinocytes or fibroblasts directly or indirectly, adrenocorticotropic hormone (ACTH) such as peptides derived from proopiomelanocortin (POMC), endothelin-1 (ET-1), stem cell factor (SCF), basic fibroblast growth factor (bFGF), nerve growth factor (NGF), or histamine synthesized from mast cells, which are directly or indirectly released from keratinocytes or fibroblasts. Within melanosomes during melanogenesis, two types of melanin, called eumelanin and pheomelanin, are synthesized: Eumelanin is a dark brown-black color with low solubility; pheomelanin is a sulfur- containing light red-yellow color with higher solubility polymer. Both are derivatives of 3,4- dihydroxyphenylalanine (DOPA) indole, synthesized from tyrosine through a series of oxidative reactions within melanosomes. The synthesis of both melanin types occurs through the enzyme tyrosinase, which catalyzes the oxidation of tyrosine to L-DOPA. This oxidation reaction is the first step of a series of reactions known as the "Raper-Mason pathway." It is considered that the conversion of tyrosine to L-DOPA is a critical and rate-limiting step in melanin biosynthesis, as the inhibition of the reaction eliminates melanin synthesis.
[0020] Follicular pigmentation depends on lots of factors such as variations depending on hair cycle, race and gender differences, variable hormone sensitivity, genetic defects, and age-related changes. Additionally, like any multi-step process, many variables affect hair pigmentation. These variables comprises growth factors, cytokines, hormones, neuropeptides and neurotransmitters, eicosanoids, cyclic nucleotides, nutrients, micro elements, and cations / anions.
[0021] In the prior art, there is a need for compositions that will increase melanin synthesis and restore the original color of hair and / or body hair, such a way that they trigger said biochemical process above, in contrast to temporary solutions such as hair dye, lotion, vitamins, minerals, and herbal oils for white hair.
[0022] Technical Problems Addressed by the Invention
[0023] The aim of the present invention is to provide a composition that allows white hair and / or body hair to return to their original colors by increasing / regulating melanin synthesis. One of the most significant advantages of the present invention is that it is applied to the scalp using the intradermal injection method (mesotherapy). After application, while the present melanocyte cells are activated, premature melanocyte cell development is promoted, and also the capacity for melanin synthesis is increased.
[0024] An advantage of the present invention is that the pharmaceutical composition of the present invention contains growth factors. The growth factors are an important class of proteins that send signals to adjust cellular effects. Depending on the relevant cell, growth factors can stimulate or suppress cell division, differentiation, migration, or genetic activities. Although they have almost similar functions and action mechanisms, hormones are considered as a different class of molecules from growth factors. The most significant difference between them is that growth factors can be secreted by many cells, while hormones are synthesized and secreted by specific endocrine glands.
[0025] An advantage of the present invention is that the pharmaceutical composition of the invention contains anticoagulants. Anticoagulants are substances that prevent blood clotting. In the preferred embodiment of the invention, the composition contains Heparin, known as a natural anticoagulant. Heparin is used parenterally for the prevention and treatment of specific venous thrombosis and pulmonary embolism. Chemically, Heparin is a mucopolysaccharide consisting of acidic polysaccharides with different chain lengths, in a glycosaminoglycan structure.
[0026] Another advantage of the present invention is that the pharmaceutical composition of the invention contains corticosteroids. Corticosteroids are steroid hormones, which are secreted by the adrenal cortex and synthetic analogs, having the same structure, and are used frequently due to their anti-inflammatory, anti-allergic, and immunosuppressive effects. The release of corticosteroids is regulated by adrenocorticotropic hormone (ACTH). Corticosteroids are used in the treatment of diseases such as asthma, bronchial hyperreactivity, aspiration and chemical pneumonia, croup syndrome, nephrotic syndrome, lupus nephritis, adrenocortical insufficiency, congenital adrenal hyperplasia, arthritis, tenosynovitis, bursitis, vasculitis, acute rheumatic carditis, dermatological diseases (eczema, seborrheic dermatitis, pemphigus), allergic diseases (urticaria, angioedema, contact dermatitis, allergic rhinitis), anaphylaxis, shock, and neurological diseases.
[0027] Another advantage of the present invention is that the pharmaceutical composition of the invention contains transferrin. Transferrins are glycoproteins, which are found in vertebrates and provide the transportation of iron (Fe+3) ions through the blood plasma. They are produced in the liver and contain binding sites for two Fe+3 ions. Transferrin glicoproteins bind iron tightly, but reversibly. Although iron that is bound to transferrin, constitutes less than 0.1 % (4 mg) of total body iron, it forms the most vital iron pool with the highest turnover rate (25 mg / 24 hours).
[0028] Another advantage of the present invention is that the pharmaceutical composition of the invention contains endothelin. They are involved in the vascular system and play a key regulatory role in many physiological and pathological events and are the largest organ in our body, limited to between blood and vascular walls (smooth muscles). Endothelins are vasoconstrictor peptides consisting of 21 amino acids. Mainly, they are produced in endothelium and play a key role in regulating vascular homeostasis (internal balance). They are one of the most potent vasoconstrictors. Endothelins have three isoforms called Endothelin-1 , Endothelin-2, and Endothelin-3, which vary in their secretion sites. Among them, Endothelin-1 is a type of endothelium which is dominantly synthesized from endothelium, is bound to a specific Endothelin A receptor in vascular smooth muscle and then causes vasoconstriction and cell growth.
[0029] A figure will be used below for a better understanding of the pharmaceutical composition of the present invention
[0030] Explanation of Figures
[0031] Figure-1 illustrates intermediate metabolites and reactions which are involved in melanin synthesis in prior art.
[0032] Detailed Description of the Invention
[0033] The present invention aims to enable white hair and / or body hair to return to their original color without any adverse side effects, unlike known temporary solutions. In accordance with this basic purpose, a pharmaceutical composition has been developed, wherein said composition provides an increase in melanin synthesis by activating melanocyte cells in hair follicles. The pharmaceutical composition of the invention is applied to the scalp through intradermal injection (mesotherapy). Through the applied composition, the existing melanocyte cells are activated, and also the development of premature melanocyte cells is promoted, thereby melanin synthesis capacities are increased. Thus, white hair and / or body hair return to their original colors due to the increase / regulation of melanin synthesis.
[0034] The pharmaceutical composition of the present invention comprises growth factors, anticoagulants, corticosteroids, transferrin, and endothelin. In the pharmaceutical composition of the present invention, the growth factor can be at least one of fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), transforming growth factor-beta (TGF-P), insulinlike growth factor (IGF), and hematopoietic growth factors. In the preferred embodiment of the invention, the growth factor is fibroblast growth factor (FGF) and insulin-like growth factor (IGF).
[0035] The anticoagulant in the pharmaceutical composition of the present invention can be at least one of heparin, sodium citrate, potassium citrate, EDTA (Ethylenediaminetetraacetic acid), or warfarin. In the preferred embodiment of the invention, the anticoagulant is heparin.
[0036] The pharmaceutical composition of the invention comprises at least one out of corticosteroid drug types that are cortisone acetate, hydrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, betamethasone, mometasone furoate, fludrocortisone acetate, flumethasone pivalate, fluocinolone acetonide, diflucortolone valerate, prednicarbate, halometasone, beclomethasone dipropionate, flunisolide, fluticasone propionate, deflazacort, and budesonide. In the preferred embodiment of the invention, the corticosteroid is hydrocortisone.
[0037] The pharmaceutical composition of the present invention contains transferrin out of plasma proteins.
[0038] Endothelin in the pharmaceutical composition of the invention can be at least one of Endothelin-1 , Endothelin-2, Endothelin-3 isoforms. In the preferred embodiment of the invention, the endothelin is Endothelin-1.
[0039] The pharmaceutical composition of the invention is prepared using the above-mentioned components as follows:
[0040] First, 9 mL of blood is taken, and then 1 mL of sodium citrate is added as an anticoagulant. This mixture is centrifuged at 3000 rpm for 5-7 minutes in a centrifuge tube, and the plasma portion is collected from the top part. Growth factors, anticoagulants, corticosteroids, transferrin, and endothelin are added to this collected plasma. These components are selected based on the above descriptions. In the preferred embodiment, fibroblast growth factor (FGF), insulin-like growth factor (IGF), heparin, hydrocortisone, transferrin, and Endothelin-1 are added to the collected plasma.
[0041] The ratios of the components are given in the table above, for 1 ml of the composition of the present invention. That is, the amount of pharmaceutical composition that is prepared is 1 mL.
[0042] In the preferred embodiment of the invention, fibroblast growth factor (FGF) and insulin-like growth factor (IGF) are preferred as growth factors. Insulin-like growth factors (IGFs) are the important regulators of energy metabolism and growth. In this sense, fibroblast growth factor (FGF) and insulin-like growth factor (IGF) help the premature melanocyte cells to become mature by activating them. In this way, the number of cells producing melanin in the follicle tissue increases. For the concentration range specified in 1 mL, the amounts below 1 ng do not show an effect, while the amounts above 100 pg may cause toxicity problems. Therefore, the safe and effective dose range is between 1 ng and 100 pg.
[0043] In the preferred embodiment of the invention, heparin acts as an anticoagulant, so increases microcirculation and enhances the nutrition of both follicle tissue and melanocyte cells. For the concentration range specified per 1 mL, the amounts below 1 pg do not show an effect, while the amounts above 100 mg may cause toxicity problems. Therefore, the safe and effective dose range is between 1 pg and 10 mg.
[0044] In the preferred embodiment of the present invention, the preferred corticosteroid is hydrocortisone. Hydrocortisone is chosen because it is able to reduce inflammation in the hair follicle tissue, thus ensures melanocyte cells in the follicle tissue to work more efficiently. For the concentration range specified per 1 mL, the amounts below 1 ng do not show an effect, while the amounts above 100 g may cause toxicity problems. Therefore, the safe and effective dose range is between 1 ng and 100 pg.
[0045] The pharmaceutical composition of the invention increases melanin synthesis in melanocyte cells, thus ensures pigmentation in hair strands. For the concentration range specified per 1 mL, the amounts below 1 ng do not show an effect, while the amounts above 100 pg may cause toxicity problems. Therefore, the safe and effective dose range is between 1 ng and 100 pg.
[0046] In the preferred application of the invention, endothelin is Endothelin-1. Endothelin-1 enhances the quality of eumelanin and pheomelanin that is synthesized from melanocyte cells, thus ensures a more noticeable change in hair. For the concentration range specified per 1 mL, the amounts below 1 ng do not show an effect, while the amounts above 100 pg may cause toxicity problems. Therefore, the safe and effective dose range is between 1 ng and 100 pg.
[0047] The above description serves as an example for the preparation of the pharmaceutical composition of the present invention, and the components can be selected and changed from the alternatives as described earlier. For example, EDTA (Ethylenediaminetetraacetic acid) can be used instead of Heparin as an anticoagulant. In another example, the nerve growth factor (NGF) can be used as the growth factor. The amounts in terms of weight are provided in the table above for 1 mL.
[0048] Application Method in Industry
[0049] The pharmaceutical composition of the present invention can be packaged in a certain amount and presented to consumers. The pharmaceutical composition of the invention can be sold in pharmacies, various health centers, cosmetic stores, etc. The pharmaceutical composition of the invention is applied to the scalp through intradermal injection method (mesotherapy)
Claims
CLAIMS1. A pharmaceutical composition that is developed to convert white body hair, particularly hair, back to its original color, characterized by comprising growth factor, anticoagulant, corticosteroid, transferrin, and endothelin.
2. A composition according to claim 1 , characterized in that said growth factor is at least one of fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), transforming growth factor (TGF-P), insulin-like growth factor (IGF), and hematopoietic growth factors.
3. A composition according to claim 1 , characterized in that said growth factor is fibroblast growth factor (FGF) and insulin-like growth factor (IGF).
4. A composition according to claim 1 , characterized in that said anticoagulant is at least one of heparin, sodium citrate, potassium citrate, EDTA (Ethylenediaminetetraacetic acid), or warfarin.
5. A composition according to claim 1 , characterized in that said anticoagulant is heparin.
6. A composition according to claim 1 , characterized in that said corticosteroid is at least one of cortisone acetate, hydrocortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, betamethasone, mometasone furoate, fludrocortisone acetate, flumethasone pivalate, fluocinolone acetonide, diflucortolone valerate, prednicarbate, halometasone, beclometasone dipropionate, flunisolide, fluticasone propionate, deflazacort, and budesonide.
7. A composition according to claim 1 , characterized in that said corticosteroid is hydrocortisone.
8. A composition according to claim 1 , characterized in that said endothelin is at least one of Endothelin-1 , Endothelin-2, and Endothelin-3.
9. A composition according to claim 1 , characterized in that said endothelin is Endothelin-1.
10. A method for preparing a pharmaceutical composition that is developed to convert white body hair, particularly hair, back to its original color, characterized by taking 9 mL of blood and adding 1 mL of sodium citrate as an anticoagulant, centrifuging the mixture at 3000 rpm for 5- 7 minutes in a centrifuge tube, collecting the plasma portion at the top part, and adding growth factor, anticoagulant, corticosteroid, transferrin, and endothelin to the collected plasma.
11. A preparation method according to claim 10, characterized by using 1 ng-100 pg of growth factor, 1 pg-10 mg of anticoagulant, 1 ng-100 pg of corticosteroid, 1 ng-100 pg of transferrin, and 1 ng-100 pg of endothelin, per 1 mL of product.
12. A preparation method according to claim 10 or 11, characterized by using fibroblast growth factor (FGF) and insulin-like growth factor (IGF) as said growth factor, heparin as said anticoagulant, hydrocortisone as said corticosteroid, and Endothelin-1 as said endothelin.
Citation Information
Patent Citations
Gray hair prophylactic / Ameliorating agent and method for screening hair active ingredient
JP2003171240A
Treatment of vitiligo by micropore delivery of cells
US20070225779A1
Compositions and Methods for Preventing and Treating Hair Growth Cycle-Related Conditions
US20090143418A1
Methods for increasing melanin content and for inducing melanocyte proliferation in-VIVO and in-vitro
WO1989009258A1
